Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04645667 · ClinicalTrials.gov registry record
Tacrolimus in Allogeneic Hematopoietic Stem Cell Transplant (HCT)
A clinical trial, sponsored by UNC Lineberger Comprehensive Cancer Center.
- Completed
- Registry status
- 38
- Enrollment target
NCT04645667 is a clinical trial that has completed, run by UNC Lineberger Comprehensive Cancer Center. The registered enrollment target is 38 participants.
The verdict
NCT04645667 has completed, sponsored by UNC Lineberger Comprehensive Cancer Center.
- COMPLETED
- Registry status
- 38 participants
- Enrollment target
Study Summary
The purpose of this research study is to evaluate tacrolimus plasma concentrations in patients who will undergo an allogeneic hematopoietic stem cell transplant (HCT). The study aims to identify associations between plasma concentrations, baseline demographic characteristics, clinical lab parameters, and genetic factors. These associations will help clinicians determine the best starting dose for tacrolimus in order to minimize risks of aGVHD and tacrolimus-induced toxicities.
Interventions
- DRUG Tacrolimus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2021-02-01 |
| Est. Completion | 2023-10-15 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04645667
The ClinicalTrials.gov registry entry for NCT04645667 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UNC Lineberger Comprehensive Cancer Center, which has 366 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tacrolimus is the first listed.
NCT04645667 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04645667 about?
NCT04645667 is a clinical study titled "Tacrolimus in Allogeneic Hematopoietic Stem Cell Transplant (HCT)". The purpose of this research study is to evaluate tacrolimus plasma concentrations in patients who will undergo an allogeneic hematopoietic stem cell transplant (HCT). The study aims to identify associations between plasma concentrations, baseline demographic characteristics, clinical lab parameters...
What is the current status of trial NCT04645667?
This trial is currently completed. The enrollment target is 38 participants. The study started on 2021-02-01. Estimated completion is 2023-10-15.
What interventions are being tested in trial NCT04645667?
The interventions under investigation include: Tacrolimus (DRUG).
Who is sponsoring clinical trial NCT04645667?
This trial is sponsored by UNC Lineberger Comprehensive Cancer Center, which has 366 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.